A detailed history of Moors & Cabot, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Moors & Cabot, Inc. holds 20,875 shares of AMGN stock, worth $6.6 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
20,875
Previous 21,794 4.22%
Holding current value
$6.6 Million
Previous $6.2 Million 5.26%
% of portfolio
0.35%
Previous 0.34%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$262.75 - $319.31 $241,467 - $293,445
-919 Reduced 4.22%
20,875 $6.52 Million
Q1 2024

May 08, 2024

BUY
$268.87 - $324.56 $238,487 - $287,884
887 Added 4.24%
21,794 $6.2 Million
Q4 2023

Feb 14, 2024

BUY
$255.7 - $288.46 $52,162 - $58,845
204 Added 0.99%
20,907 $6.02 Million
Q3 2023

Nov 07, 2023

BUY
$218.65 - $271.46 $206,186 - $255,986
943 Added 4.77%
20,703 $5.56 Million
Q2 2023

Aug 09, 2023

SELL
$214.27 - $253.37 $106,706 - $126,178
-498 Reduced 2.46%
19,760 $4.39 Million
Q1 2023

May 04, 2023

BUY
$225.79 - $275.2 $2,032 - $2,476
9 Added 0.04%
20,258 $4.9 Million
Q4 2022

Feb 09, 2023

BUY
$229.03 - $291.01 $1.68 Million - $2.13 Million
7,319 Added 56.6%
20,249 $5.32 Million
Q4 2022

Feb 06, 2023

SELL
$229.03 - $291.01 $1.4 Million - $1.77 Million
-6,094 Reduced 32.03%
12,930 $3.4 Million
Q3 2022

Nov 07, 2022

BUY
$224.46 - $253.15 $194,831 - $219,734
868 Added 4.78%
19,024 $4.29 Million
Q2 2022

Aug 08, 2022

SELL
$230.71 - $256.74 $57,908 - $64,441
-251 Reduced 1.36%
18,156 $4.42 Million
Q1 2022

May 13, 2022

BUY
$219.27 - $242.57 $795,292 - $879,801
3,627 Added 24.54%
18,407 $4.45 Million
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $217,773 - $249,222
1,095 Added 8.0%
14,780 $3.33 Million
Q3 2021

Dec 08, 2021

BUY
$212.27 - $248.7 $2.9 Million - $3.4 Million
13,685 New
13,685 $2.91 Million
Q3 2021

Nov 05, 2021

SELL
$212.27 - $248.7 $2.87 Million - $3.37 Million
-13,534 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$233.58 - $259.14 $31,066 - $34,465
133 Added 0.99%
13,534 $3.3 Million
Q1 2021

May 12, 2021

SELL
$221.91 - $258.6 $244,544 - $284,977
-1,102 Reduced 7.6%
13,401 $3.33 Million
Q4 2020

Feb 11, 2021

SELL
$216.38 - $257.67 $2.74 Million - $3.26 Million
-12,652 Reduced 46.59%
14,503 $3.33 Million
Q3 2020

Nov 09, 2020

SELL
$234.65 - $260.95 $132,577 - $147,436
-565 Reduced 2.04%
27,155 $6.9 Million
Q2 2020

Aug 13, 2020

BUY
$197.81 - $242.74 $327,968 - $402,462
1,658 Added 6.36%
27,720 $6.55 Million
Q1 2020

May 12, 2020

SELL
$182.24 - $241.7 $856,528 - $1.14 Million
-4,700 Reduced 15.28%
26,062 $5.28 Million
Q4 2019

Jan 28, 2020

SELL
$189.21 - $243.2 $130,176 - $167,321
-688 Reduced 2.19%
30,762 $7.4 Million
Q3 2019

Oct 22, 2019

BUY
$174.11 - $208.62 $78,001 - $93,461
448 Added 1.45%
31,450 $6.09 Million
Q2 2019

Jul 18, 2019

SELL
$166.7 - $195.41 $49,843 - $58,427
-299 Reduced 0.96%
31,002 $5.7 Million
Q1 2019

May 06, 2019

SELL
$180.87 - $203.88 $5.66 Million - $6.38 Million
-31,301 Reduced 50.0%
31,301 $5.94 Million
Q1 2019

May 01, 2019

BUY
$180.87 - $203.88 $5.46 Million - $6.16 Million
30,191 Added 93.15%
62,602 $11.9 Million
Q4 2018

Feb 13, 2019

BUY
$178.4 - $208.25 $73,500 - $85,799
412 Added 1.29%
32,411 $6.3 Million
Q3 2018

Nov 14, 2018

BUY
$185.29 - $208.89 $448,587 - $505,722
2,421 Added 8.19%
31,999 $6.63 Million
Q2 2018

Aug 14, 2018

SELL
$166.05 - $186.51 $254,886 - $286,292
-1,535 Reduced 4.93%
29,578 $5.45 Million
Q1 2018

May 18, 2018

SELL
$169.43 - $198.0 $145,879 - $170,478
-861 Reduced 2.69%
31,113 $5.3 Million
Q4 2017

Feb 13, 2018

BUY
$168.79 - $188.59 $335,216 - $374,539
1,986 Added 6.62%
31,974 $5.56 Million
Q3 2017

Nov 16, 2017

BUY
$167.29 - $191.0 $238,890 - $272,748
1,428 Added 5.0%
29,988 $5.6 Million
Q2 2017

Aug 15, 2017

BUY
N/A
28,560
28,560 $4.91 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.